Program
entecavir
Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.
Drug pageEntecavir: every studyMany companies study it; this page follows only the 32 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 240 open or running | phase 4since Aug 29, 2006 | May 4, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 40 open or running | phase 4since Jan 30, 2008 | Jan 30, 2008 | none ahead |
| Ascentage Pharma Group Internationalits history only | 11 open or running | phase 2since Sep 24, 2020 | Sep 24, 2020 | none ahead |
| Aucta Pharmaceuticalsits history only | 10 open or running | phase 1since Jul 27, 2017 | Jul 27, 2017 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 4since Jul 26, 2015 | Jul 26, 2015 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | no phasesince Jan 22, 2019 | Jan 22, 2019 | none ahead |
Also a collaborator on its studies: ICON Clinical Research and CPR Pharma Services Pty Ltd, Australia.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since May 4, 2002.
- Oct 26, 2006Phase 4 study in Hepatitis B, ChronicNCT00393484 · 122 enrolled · Korea, Republic of
- Nov 1, 2006Phase 3 study in Hepatitis B, ChronicNCT00395018 · 109 enrolled · United States, Argentina, Australia and more
- Dec 11, 20062 phase 3 studies in Hepatitis B, ChronicNCT00410202, NCT00410072
- Jan 16, 2007Phase 2 study in Hepatitis B, ChronicNCT00423891 · 64 enrolled · United States, Argentina, Belgium and more
- Jan 18, 2008Phase 3 study in Hepatitis B, ChronicNCT00605384 · 4 enrolled · United States, Belgium, Germany and more
- Jul 17, 2008Phase 4 study in Hepatitis B, ChronicNCT00718887 · 228 enrolled · China
- Sep 8, 2009Phase 3 study in Hepatitis B, ChronicNCT00975091 · 600 enrolled
- Sep 29, 2009Phase 4 study in Hepatitis B, ChronicNCT00986778
- Nov 24, 20092 phase 2 studies in Hepatitis B, ChronicNCT01020565, NCT01022801
- Dec 17, 20092 phase 2 studies in Hepatitis B, ChronicNCT01037166, NCT01037062
- Feb 3, 2010Phase 3 study in Hepatitis B, ChronicNCT01063036 · 144 enrolled · France, Germany, Italy and more
- Mar 2, 2010Phase 3 study in Hepatitis B, ChronicNCT01079806 · 180 enrolled · United States, Argentina, Belgium and more
- Sep 16, 2011Phase 2 study in Hepatitis BNCT01438424 · 1,053 enrolled
- Mar 14, 2017Phase 1 study in Hepatitis BNCT03083821 · 6 enrolled · Japan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 24 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03083821Hepatitis B · Japan | 1 | Completed | Dec 19, 2017 | 6 |
| NCT01438424Hepatitis B | 2 | Completed | Dec 2009 | 1,053 |
| NCT01079806Hepatitis B, Chronic · United States, Argentina, Belgium and more | 3 | Completed | Mar 31, 2013 | 180 |
| NCT01063036Hepatitis B, Chronic · France, Germany, Italy and more | 3 | Completed | Nov 2012 | 144 |
| NCT01037166Hepatitis B, Chronic · Japan | 2 | Completed | Feb 2005 | 84 |
| NCT01037062Hepatitis B, Chronic · Japan | 2 | Completed | Dec 2006 | 282 |
| NCT01022801Hepatitis B, Chronic | 2 | Completed | Mar 2005 | 120 |
| NCT01020565Hepatitis B, Chronic | 2 | Completed | Feb 2005 | 60 |
| NCT00986778Hepatitis B, Chronic | 4 | Withdrawn | Dec 2012 | 0 |
| NCT00975091Hepatitis B, Chronic | 3 | Completed | Aug 2007 | 600 |
| NCT00718887Hepatitis B, Chronic · China | 4 | Completed | Dec 2009 | 228 |
| NCT00605384Hepatitis B, Chronic · United States, Belgium, Germany and more | 3 | Terminated | Feb 2009 | 4 |
| NCT00423891Hepatitis B, Chronic · United States, Argentina, Belgium and more | 2 | Completed | Aug 31, 2013 | 64 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Jan 2011 | 629 |
| NCT00410072Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Oct 2010 | 669 |
| NCT00395018Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Mar 2011 | 109 |
| NCT00393484Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Jan 2009 | 122 |
| NCT00371150Hepatitis B · United States, Brazil, Mexico and more | 4 | Completed | Mar 2011 | 131 |
| NCT00096785Hepatitis B · United States, Canada, Hong Kong and more | 3 | Completed | Jan 2006 | 69 |
| NCT00065507Hepatitis B · United States, Brazil, Canada and more | 3 | Completed | Oct 2008 | 195 |
| NCT00051038Hepatitis B · United States | 3 | Completed | Oct 2005 | |
| NCT00036608Hepatitis B, Chronic · United States | 3 | Completed | Feb 2005 | |
| NCT00035789Hepatitis B, Chronic · United States | 3 | Completed | May 2005 | |
| NCT00035633Hepatitis B, Chronic · United States | 3 | Completed | Feb 2005 |
How it is read
Names in the registry
- “Entecavir”, 28 entries
- “entecavir”, 4 entries
- “Entecavir (ETV)”, 2 entries
- “Entecavir + Tenofovir”, 2 entries
- “P1101 + Nivolumab + Entecavir”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 34 studies
- Hepatitis B, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.